4D Molecular Therapeutics, Inc. Form 4 Filings

4D Molecular Therapeutics, Inc. (FDMT) reported that President and Chief Executive Officer David Kirn, who is also a director, sold 58,333 shares of common stock on September 14, 2026 in an open-market or private transaction at a weighted average price of $13.903 per share. The trade was executed under a Rule 10b5-1 trading plan adopted on January 9, 2026, with individual sale prices ranging from $13.43 to $14.15 per share, and left him holding 767,486 shares of common stock directly.

4D Molecular Therapeutics, Inc. (FDMT) reported that its Chief Legal Officer, Scott Bizily, exercised options for 584 shares of common stock on September 1, 2026 at an exercise price of $6.49 per share and sold the same 584 shares at $14.00 per share. The option exercise and related sale were made under a Rule 10b5-1 trading plan adopted on January 13, 2026. Following the exercise, 2,959 option shares remain outstanding from this award, which vests in equal monthly installments over four years starting June 16, 2022.

4D Molecular Therapeutics, Inc. (FDMT) reported that President and Chief Executive Officer David Kirn exercised stock options for 50,000 shares of common stock at an exercise price of $4.14 per share, reducing that option position to 217,500 options remaining. He then sold a total of 69,076 common shares in open-market transactions on August 19, 2026, including 43,149 shares at a weighted average price of $15.3566 (within a range of $14.91–$15.84) and 25,927 shares at a weighted average price of $16.4173 (within a range of $15.97–$16.65). The filing states these trades were made pursuant to a Rule 10b5-1 trading plan adopted on January 9, 2026.

4D Molecular Therapeutics, Inc. executive Scott Bizily, Chief Legal Officer, reported paired option exercises and stock sales in FDMT. On August 13, 2026 and August 17, 2026, Bizily exercised stock options covering 1,635 shares of common stock on each date at an exercise price of $4.14 per share, converting a total of 3,270 stock option rights into common shares. On each of those dates, he then sold 1,635 shares of common stock in open-market or private transactions at per-share prices of $12.00 and $12.20, respectively. These sales were made pursuant to a Rule 10b5-1 trading plan adopted on January 13, 2026. The exercised options relate to an award that vests monthly, with 1/48th of the underlying shares vesting each month starting on March 6, 2025 until fully vested on the fourth anniversary, while Bizily remains a service provider.

4D Molecular Therapeutics, Inc. director and officer David Kirn sold 26,842 shares of common stock on August 4, 2026 at a weighted average price of $10.2301 per share. The sale was executed in multiple trades between $10.07 and $10.42 pursuant to a 10b5-1 trading plan adopted January 9, 2026. After this transaction, he directly owns 844,895 common shares.

4D Molecular Therapeutics, Inc. President and Chief Executive Officer David Kirn sold 12,415 shares of common stock on August 3, 2026 at a weighted average price of $10.0461 per share, pursuant to a 10b5-1 trading plan adopted January 9, 2026, and now directly holds 871,737 shares.

4D Molecular Therapeutics, Inc. director and officer David Kirn reported three open-market sales totaling 58,333 shares of common stock on July 9–10, 2026, at weighted average prices of $12.8656, $12.8355 and $12.0107 per share under a Rule 10b5-1 trading plan. After these transactions, he directly holds 884,152 shares of FDMT common stock.

4D Molecular Therapeutics Chief Legal Officer Scott Bizily reported an option exercise-and-sale transaction in company stock. On June 30, 2026, he sold 6,566 shares of common stock at $14.00 per share in an open-market transaction made pursuant to a Rule 10b5-1 trading plan adopted on January 13, 2026.

On the same date, he exercised stock options covering 5,752 shares at an exercise price of $6.49 per share and 814 shares at $4.14 per share, converting these derivative awards into common shares. The options exercised were from grants originally scheduled to vest monthly over four years and carried expiration dates in 2032 and 2035.

4D Molecular Therapeutics Chief Legal Officer Scott Bizily reported an exercise-and-sell stock transaction. On June 23, 2026, he exercised options to acquire 9,810 shares of common stock at $4.14 per share, then sold 9,810 shares in an open-market trade at $12.00 per share.

After these transactions, he holds 8,617 common shares directly and 63,785 stock options with a $4.14 exercise price expiring in 2035. A footnote also notes 5,023 shares previously purchased under the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.

4D Molecular Therapeutics director and officer David Kirn reported an open-market sale of 114,746 shares of Common Stock at a weighted average price of $10.4653 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on January 9, 2026, meaning it was pre-scheduled rather than timed discretionarily. After this sale, Kirn directly holds 942,485 shares of the company’s stock.

4D Molecular Therapeutics director Shawn Tomasello received a new stock option grant as part of non-employee director compensation. The award covers options to buy 50,000 shares of common stock at an exercise price of $9.42 per share, expiring on June 16, 2036.

One-third of the option vests on June 17, 2027, with the remaining shares vesting in equal monthly installments until fully vested on June 17, 2029, provided she continues serving the company. The option will vest in full if a Change in Control occurs under the company’s 2020 Incentive Award Plan.

4D Molecular Therapeutics director Charles Theuer received a grant of stock options for 50,000 shares of common stock as part of non-employee director compensation. The options have an exercise price of $9.42 per share and expire on June 16, 2036.

One-third of the options vest on June 17, 2027, with the remainder vesting in equal monthly installments until full vesting on June 17, 2029, contingent on continued service. The options also vest in full if a Change in Control, as defined in the 2020 Incentive Award Plan, is completed.

4D Molecular Therapeutics director Nancy Miller-Rich received a new stock option grant for 50,000 shares of common stock. The options have an exercise price of $9.42 per share and were granted at no cost as part of the company’s non-employee director compensation program.

The option vests over time: one-third of the shares vest on June 17, 2027, with the remaining shares vesting in equal monthly installments until fully vested on June 17, 2029, assuming continued service. The options will also vest in full if a Change in Control occurs under the 2020 Incentive Award Plan.

4D Molecular Therapeutics director Susannah Gray received a grant of stock options for 50,000 shares of common stock. The options have an exercise price of $9.42 per share and expire on June 16, 2036. One-third of the options vest on June 17, 2027, with the remainder vesting in equal monthly installments until fully vested on June 17, 2029, as long as she continues serving the company. The options were automatically granted under the non-employee director compensation program, and this grant brings her direct option holdings reported in this filing to 50,000 shares.

4D Molecular Therapeutics director John F. Milligan received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $9.42 per share and were automatically granted under the non-employee director compensation program. One-third vests on June 17, 2027, with the rest vesting in equal monthly installments until fully vested on June 17, 2029, or sooner upon a Change in Control, and they expire on June 16, 2036.

4D Molecular Therapeutics director Glenn Sblendorio received a grant of stock options for 50,000 shares of Common Stock. The options have an exercise price of $9.42 per share and expire on June 16, 2036, and are held directly.

The grant was automatically made under the company’s non-employee director compensation program. One-third of the options vest on June 17, 2027, with the remaining shares vesting in equal monthly installments until full vesting on June 17, 2029, or earlier upon a Change in Control under the 2020 Incentive Award Plan. Following this award, Sblendorio holds options for 50,000 shares from this grant.

4D Molecular Therapeutics director Jacob Chacko received a new stock option grant covering 50,000 shares of common stock. The option has an exercise price of $9.42 per share and expires on June 16, 2036. It was granted automatically under the company’s non-employee director compensation program.

The option vests as to one-third of the shares on June 17, 2027, then in equal monthly installments until fully vested on June 17, 2029, contingent on his continued service. The award will also vest in full upon a Change in Control as defined in the 2020 Incentive Award Plan. Following this grant, he holds options for 50,000 shares directly.

4D Molecular Therapeutics director and officer David Kirn reported an open‑market sale of 1,922 shares of Common Stock at a weighted average price of $10.0197 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on January 9, 2026 and was carried out in multiple trades between $10.00 and $10.055 per share.

Following this sale, Kirn directly holds 1,057,231 shares of the company’s common stock, indicating he retained a substantial position after the transaction.

4D Molecular Therapeutics granted Chief Executive Officer David Kirn a stock option covering 750,000 shares of common stock. The option has an exercise price of $9.88 per share and expires on March 24, 2036.

The award vests over four years, with 1/48 of the shares vesting monthly starting on March 25, 2026, so long as he continues as a service provider. Following this grant, the filing shows 750,000 derivative securities (options) held directly by Kirn.

4D Molecular Therapeutics reported a stock option grant to Chief Legal Officer Scott Bizily. The award covers 217,000 options for common stock at an exercise price of $9.88 per share and expires on March 24, 2036.

The options vest in equal monthly installments over four years, with 1/48th of the underlying shares vesting on each monthly anniversary of March 25, 2026, so long as Bizily remains a service provider. This is a compensation-related equity grant, not an open-market share purchase or sale.

4D Molecular Therapeutics, Inc. reported that officer Christopher Paul Simms received a grant of stock options covering 219,000 shares of common stock. The options have an exercise price of $9.88 per share and expire on March 24, 2036.

According to the terms, 1/48 of the underlying shares will vest each month starting on March 25, 2026, so long as Simms remains a service provider, with full vesting on the fourth anniversary of that date. Following this grant, he holds options for 219,000 shares directly.

4D Molecular Therapeutics VP Ashoo Gupta reported routine equity compensation activity. On March 20, 2026, Gupta exercised restricted stock units (RSUs) into 1,086 shares of common stock at a conversion price of $0.00 per share.

On the same date, 390 common shares were sold at $8.61 per share in an automatic “sell-to-cover” transaction to satisfy tax withholding obligations, as described in the footnotes, rather than a discretionary trade. Following these transactions, Gupta directly held 47,055 common shares, plus RSU awards that continue to vest beginning on June 20, 2025 in scheduled quarterly installments while serving as a company service provider.

4D Molecular Therapeutics director Glenn Sblendorio reported a grant of stock options in the company. On January 5, 2026, he received 45,000 stock options to buy common shares at an exercise price of $7.30 per share. These options expire on January 4, 2036.

One-third of the options vest on the first anniversary of January 5, 2026, and the remaining two-thirds vest in equal monthly installments over the following two years. After this grant, Sblendorio beneficially owned 45,000 derivative securities directly.

4D Molecular Therapeutics director Charles Theuer reported exercising a stock option for 9,333 shares of common stock at $1.14 per share on December 12, 2025. The transaction is shown as an acquisition of common stock following the exercise of a fully vested stock option originally granting the right to buy 9,333 shares at $1.14, with an expiration date of March 9, 2026. After this transaction, Theuer directly beneficially owned 41,684 shares of 4D Molecular Therapeutics common stock and held no remaining derivative securities from this option grant.

4D Molecular Therapeutics, Inc. reported an equity award for its Chief Financial Officer. The officer received a stock option covering 480,000 shares of common stock at an exercise price of $10.51 per share, dated 12/09/2025, with the option expiring on 12/08/2035.

According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of the November 17, 2025 vesting commencement date. The remaining shares vest in 36 equal monthly installments so that the option is fully vested on the fourth anniversary of that date, provided the officer continues as a service provider to the company.

4D Molecular Therapeutics, Inc. (FDMT) reported an insider equity transaction by its Chief Legal Officer on a Form 4. On 11/17/2025, the officer exercised a stock option to buy 1,635 shares of common stock at $4.14 per share and, on the same date, sold 1,635 shares at $10.59 per share under a Rule 10b5-1 trading plan adopted on June 6, 2025. After these trades, the officer directly holds 3,594 shares of common stock and 75,230 stock options. The option underlying this transaction covers 1,635 shares and vests in equal monthly installments over four years starting from March 6, 2025, as long as the officer continues to serve the company.

4D Molecular Therapeutics (FDMT) reported an insider transaction by its Chief Legal Officer. On 10/24/2025, the officer exercised 1,084 stock options at $6.49 per share and sold 2,678 common shares at $12 per share under a Rule 10b5-1 plan adopted on June 6, 2025.

Following these transactions, the officer beneficially owned 3,594 common shares directly. The filing also shows 9,295 stock options beneficially owned after the reported activity, with the option grant expiring on 06/17/2032 and vesting monthly from the June 16, 2022 commencement date until the fourth anniversary.

4D Molecular Therapeutics (FDMT) Form 4: the Chief Legal Officer reported an option exercise and a same‑day sale on 10/16/2025. The insider exercised 1,635 stock options at $4.14 per share (Code M) and sold 1,635 common shares at $10.17 per share (Code S) pursuant to a Rule 10b5‑1 plan adopted on June 6, 2025.

Following these transactions, the insider reported 5,188 common shares directly owned and 76,865 derivative securities (stock options) beneficially owned. The exercised option was part of an award vesting monthly in 1/48th increments starting March 6, 2025, with full vesting on the fourth anniversary, and carries an expiration date of March 5, 2035.

4D Molecular Therapeutics (FDMT) reported an insider transaction on a Form 4. The company’s Chief Legal Officer sold 2,408 shares of common stock at $10 on October 9, 2025, pursuant to a Rule 10b5-1 trading plan adopted on June 6, 2025.

Following the sale, the reporting person beneficially owned 5,188 shares, held directly. The filing was made by one reporting person.